SCHEMBL3269809

SCHEMBL3269809

O=C(Nc1cccnn1)N1CCN(c2ccnc(-c3ccccc3)c2)CC1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 15/20 0.69
HCAR2 Q8TDS4 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
MEN1 O00255 1/20 0.44
HCRTR1 O43613 1/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.43
GSK3B P49841 1/20 0.43
DYRK1A Q13627 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3442510 0.86 FAAH (0.61) FAAHTRPV1MEN1HCRTR1USP2
SCHEMBL3268532 0.84 FAAH (0.70) FAAH
SCHEMBL3268636 0.83 FAAH (0.78) FAAHHCAR2GAA
SCHEMBL3269595 0.82 FAAH (1.00) FAAHTRPV1MAPT
SCHEMBL3442148 0.82 FAAH (0.71) FAAHTRPV1POLBMAPT
SCHEMBL3274877 0.81 FAAH (0.58) FAAHTRPV1MEN1HCRTR1USP2
SCHEMBL3268737 0.81 FAAH (0.71) FAAHTRPV1MEN1HCRTR1USP2
SCHEMBL3268847 0.80 FAAH (0.68) FAAHHCAR2TRPV1
SCHEMBL3275315 0.79 FAAH (0.68) FAAHTRPV1
SCHEMBL3770860 0.78 FAAH (0.68) FAAHCYP1A2CYP3A4MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885HCAR2 34/4885TRPV1 6/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885HCAR2 34/4885TRPV1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.